

VRL/SEC/EXCHANGE

10.11.2025

<p>National Stock Exchange of India Ltd. 5th Floor, Exchange Plaza Bandra (E), Mumbai- 400051 Script Code: VENUSREM</p>	<p>BSE Limited 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400051 Script Code: 526953</p>
--	--

Sub.: Outcome of Board Meeting date 10th November 2025 and Unaudited Financial Results for the quarter and half year ended on 30th September 2025.

Dear Sir/ Madam,

This has reference to the meeting of Board of Directors held on 10th November 2025 inter alia considered and approved Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended on 30th September 2025 along with Limited Review report.

Unaudited Financial Results for the quarter and half year ended on 30th September 2025 along with the Limited Review report are enclosed herewith.

Meeting commenced at 02:45 pm and concluded at 05.55 pm.

Kindly take the above information on your record.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED

Neha
(Company Secretary)
M.No. 8374

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany





J.K JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1136-37, Sector 22-B Chandigarh-160022,
0172-2704536-37,
Email:- jkjcaps@rediffmail.com

Independent Auditor's Limited Review Report on Unaudited Quarterly Consolidated financial results of Venus Remedies Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To
The Board of Directors
VENUS REMEDIES LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **VENUS REMEDIES LIMITED** ("the Holding Company") and its subsidiary (collectively referred to as 'the Group'), for the Quarter ended 30th September 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following Subsidiary:
 - i. Venus Pharma Gmbh
 - ii. Venus Pharma Kft (Subsidiary of Venus Pharma GmbH)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the report of referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. **Emphasis of matter**

1. We draw attention to Note 4 of the accompanying Statement, which describes the financial condition of the Company's overseas wholly owned subsidiary, *Venus Pharma GmbH*. As stated in the note, the subsidiary's net worth has turned negative by INR 132.10 Lakhs as at the reporting date, which indicates the existence of a material uncertainty that may cast significant doubt on its ability to continue as a going concern.

We have considered the management's assessment of the going concern assumption, including their future projections, proposed financial support from the holding company, and revival strategies. Based on representations obtained and the disclosures made in the Statement, management is of the view that this is a temporary phase and the subsidiary's financial position is expected to improve and stabilize by the end of the financial year 2025-26.

2. We draw attention to Note 5 of the accompanying Statement, which describes the outstanding share application money amounting to INR 2,859.72 Lakhs in respect of *Venus Pharma GmbH*, a wholly owned subsidiary of the Company. The share allotment against this amount has been pending as it is not mandatory under the applicable laws of Germany.

Management has represented that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations carried out by the Management in FY 2025-2026. Although the subsidiary is currently facing financial challenges, the Company has reiterated its intention to provide the necessary financial and operational support during the transition period.

Our opinion is not modified in respect of above matters.

7. **Other Matter**

The accompanying statement of quarterly unaudited standalone financial results includes the unaudited interim financial results and other financial information in respect of two subsidiaries, whose financial result and other information without giving the effect to the elimination of the intra group transaction reflect groups as:



Name of Subsidiary	Revenue (INR in Crores)	Net Profit/(Loss) (INR in Crores)	Total comprehensive Income (INR in Crores)
Venus Pharma GmbH	10.61	(1.21)	(1.21)
Venus Pharma Kft	Nil	Nil	Nil

Further, subsidiary is located outside India, whose financial results have been prepared in accordance with accounting principles generally accepted in India, and which have been reviewed by us under standard of auditing applicable in India. Our opinion, in so far as it relates to the balances and affairs of the subsidiary, is based on our audit report.

Our conclusion on the Statement is not modified in respect of the above matter.

For J.K Jain & Associates
Chartered Accountants
FRN-004025N

CA Anurag Verma
Partner
M. No. 555033
UDIN: 25555033BMNSRZ8023
Date: 10th November 2025

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

(Rs. In Crores except EPS)

S. No.	PARTICULARS	QUARTER ENDED ON			HALF YEAR ENDED ON		YEAR ENDED ON
		30/09/2025	30/06/2025	30/09/2024	30/09/2025	30/09/2024	31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue						
	(a) Revenue from Operations	192.75	137.18	170.10	329.93	278.71	652.89
	(b) Other Income	1.71	3.41	7.93	5.12	9.52	15.95
	Total Income	194.46	140.59	178.03	335.05	288.22	668.85
2	Expenses						
	(a) Cost of Material Consumed	106.51	71.33	77.45	177.84	147.03	348.77
	(b) Purchase of stock in trade	1.86	2.27	8.38	4.13	17.41	25.04
	(c) Changes in Inventories of finished goods, work -in -progress & Stock In Trade	(1.06)	0.55	21.89	(0.51)	0.91	4.81
	(d) Employee benefits expense	22.97	20.31	21.57	43.28	39.77	80.49
	(e) Finance Cost	0.01	0.01	0.02	0.02	0.04	0.07
	(f) Depreciation & amortization expense	6.17	6.18	6.40	12.35	12.38	22.51
	(g) Selling ,Manufacturing and Administrative expenses	27.16	23.35	28.46	50.51	45.39	107.16
	(h) Research & Development expenses	4.35	3.99	4.78	8.34	9.36	18.08
	Total Expense	167.97	127.99	168.96	295.96	272.31	606.93
3	Profit before taxes (1-2)	26.49	12.60	9.07	39.09	15.92	61.92
4	Exceptional Items	-	-	-	-	-	9.91
5	Profit after exceptional items (3 + 4)	26.49	12.60	9.07	39.09	15.92	71.83
	EBIDTA (3+2e+2f)	32.67	18.80	15.49	51.46	28.34	84.49
6	Tax Expense						
A	Current Tax	6.45	3.70	3.73	10.15	6.26	18.93
B	Deferred Tax	(0.09)	(0.69)	1.83	(0.79)	4.92	4.65
C	Tax expense related to previous year	-	-	-	-	-	2.93
7	Net Profit /(Loss) for the period (5 - 6)	20.13	9.60	3.51	29.73	4.74	45.32
8	Other Comprehensive Income						
A	(I) Items that will not be classified to profit & loss	(0.12)	(0.12)	(0.05)	(0.24)	(0.09)	(0.48)
B	(I) Foreign Currency Translation Reserve	0.74	(1.25)	(0.26)	(0.51)	(0.41)	(0.25)
C	(I) Items that will be classified to profit & loss	0.63	3.73	2.87	4.36	3.19	0.05
	(II) Income tax relating to items that may be reclassified to Profit & loss	-	-	(0.72)	-	(0.80)	-
	Total other comprehensive Income Net of Income Tax	1.26	2.36	1.84	3.61	1.88	(0.68)
9	Total comprehensive Income for the period (7+I-8)	21.39	11.95	5.35	33.34	6.62	44.64
10	Paid up equity share capital (Face Value of Equity Shares)	13.37	13.37	13.37	13.37	13.37	13.37
		10	10	10	10	10	10
11	Other Equity	-	-	-	-	-	547.58
12	Earning per share (of Rs. 10/- each)						
	(a) Basic	15.06	7.18	2.63	22.24	3.54	33.90
	(b) Diluted	15.06	7.18	2.63	22.24	3.54	33.90



For VENUS REMEDIES LIMITED

 CHAIRMAN & MANAGING DIRECTOR

Unaudited Statement of Consolidated Assets and Liabilities

(₹ In Crore)

Particulars	As at 30/09/2025 (Unaudited)	As at 31/03/2025 (Audited)
ASSETS		
Non-Current Assets		
(a) Property, Plant & Equipment	124.92	124.70
(b) Capital work in progress	34.01	26.39
(c) Intangible Assets	99.41	104.72
(d) Right of Use Assets	13.14	-
(e) Financial Assets		
(i) Investments	0.02	0.02
(ii) Other Financial Assets	6.71	5.70
(f) Other Non-Current Assets	4.20	2.47
Total Non Current Assets	282.41	264.00
Current Assets		
(a) Inventories	106.67	100.49
(b) Financial Assets		
(i) Investments	193.16	84.09
(ii) Trade Receivables	96.57	112.22
(iii) Cash and Cash Equivalents	21.99	57.52
(iv) Others Bank Balances	20.60	22.58
(v) Other Financial Assets	0.44	0.86
(c) Current Tax Assets	9.34	10.86
(d) Other Current Assets	36.92	63.10
Total Current Assets	485.69	451.72
Total Assets	768.10	715.72
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	13.37	13.37
(b) Other Equity	580.94	547.58
Total equity	594.31	560.95
Liabilities		
Non-Current Liabilities		
(a) Provisions	3.19	2.90
(b) Deferred Tax Liabilities (net)	15.81	15.58
(c) Financial Liabilities		
(i) Lease Liabilities	11.74	-
Total Non-Current Liabilities	30.74	18.48
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1.34	1.69
(ii) Trade payables		
(A) Total outstanding dues of micro enterprises and small enterprises	11.25	6.05
other than micro and small enterprises	86.63	85.81
(iii) Lease Liabilities	1.30	-
(iv) Other Financial Liabilities	37.72	31.39
(b) Other Current Liabilities	2.55	5.27
(c) Provisions	2.26	6.08
Total Current Liabilities	143.05	136.29
Total Equity and Liabilities	768.10	715.72




For VENUS REMEDIES LIMITED

 CHAIRMAN & MANAGING DIRECTOR

**UNAUDITED STATEMENT OF CONSOLIDATED CASH FLOW FOR THE PERIOD ENDED
30TH SEPTEMBER 2025**

		(₹ in Crore)	
PARTICULARS		For the Year ended 30/09/2025	For the Year ended 30/09/2024
		Unaudited	Unaudited
A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit Before Tax	39.10	15.92
	Adjustment for Depreciation	12.35	12.38
	Adjustment for loss/(profit) on sale of Property plant and Equipment	0.07	0.78
	Interest Expense	0.02	0.04
	Rent Received	(0.21)	(0.20)
	Gain on sale of Mutual Fund	(1.55)	(0.75)
	Interest Received	(1.22)	(2.07)
	Operating Profit before working capital changes	48.56	26.10
	Less Tax Paid	(9.22)	(7.12)
	Adjustments for increase /decrease in Current Assets	3.65	(67.61)
	Decrease / Increase in Current Liabilities/ Provisions	45.55	76.63
	Decrease / Increase in Others Non-Current Assets and Other Financial Assets	(2.73)	(2.93)
	Provision for gratuity,leave encashment and Income Tax	(4.70)	0.53
	Net Cash Flow from operating activities (A)	81.11	25.60
B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Rent Received	0.21	0.20
	Purchase of Property plant and equipment	(12.89)	(3.02)
	Right of Use Assets	(13.30)	-
	Purchase of Intangible Assets	-	(8.45)
	Sale of Property plant and equipment	0.06	0.13
	Investment in Mutual funds / Fixed Deposit	(103.71)	(33.48)
	Gain on sale of Mutual Fund	1.55	0.75
	Interest Received	1.22	2.07
	Net Cash Flow from Investing Activities (B)	(126.86)	(41.80)
C)	CASH FLOW FROM FINANCING ACTIVITIES		
	Proceeds from term Loans (Net)	(0.36)	(0.42)
	Lease Liabilities	13.05	-
	Interest Expense	(0.02)	(0.04)
	Net Cash from Financing Activities (C)	12.67	(0.46)
	Net Increase in Cash & Cash Equivalents (A+B+C)	(33.08)	(16.66)
	Unrealised Loss/(gain) on foreign currency cash and cash equivalents	(2.45)	(0.98)
	Opening Cash & Cash Equivalents	57.52	48.96
	Closing Cash & Cash Equivalents	21.99	31.32





Notes to the consolidated financial results: -

1. The above Consolidated Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 10th November 2025. The statutory auditors of the holding company have carried out limited review of the above Consolidated Financial Result for the quarter and half year ended 30th September 2025, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The Consolidated Financial Results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
3. The parent company has a wholly owned subsidiary named Venus Pharma GmbH in Germany. Venus Pharma Kft is a step-down subsidiary of the parent company through Venus Pharma GmbH. The consolidated financial results include the results of both Venus Pharma GmbH and its step-down subsidiary Venus Pharma Kft.
4. The net worth of the Parent Company's overseas wholly owned subsidiary, *Venus Pharma GmbH*, net worth has been eroded by INR 132.10 lakhs. But management's assessment for the going concern assumption, including future projections, proposed financial support and revival strategies, the subsidiary's financial position is expected to improve and stabilize by the end of the financial year 2025-26.
5. The share application amounts to INR 2859.72 Lakhs in respect of Venus Pharma GmbH, a wholly owned subsidiary of the Parent Company is pending for allotment as share allotment against this amount is not a regulatory requirement under the applicable laws of Germany. The Management has reiterated that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations it carried out in FY25.
6. Previous year / period figures have been regrouped/ reclassified wherever necessary.
7. The group has only one reportable segment namely "Pharmaceuticals"



**For and on behalf of Board of Directors
for VENUS REMEDIES LIMITED**


Pawan Chaudhary

(Managing Director)

DIN: 00435503

Date: 10.11.2025



J.K JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1136-37, Sector 22-B Chandigarh-160022,
0172-2704536-37,
Email:- jkicaps@rediffmail.com

Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Venus Remedies Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

VENUS REMEDIES LIMITED

1. We have reviewed accompanying statement of unaudited standalone financial results of **VENUS REMEDIES LIMITED** ("the Company"), for the Quarter ended 30th September 2025 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement which is responsibility of company's Management has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to report a conclusion on these statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. Emphasis of matter:

1. We draw attention to Note 4 of the accompanying Statement, which describes the financial condition of the Company's overseas wholly owned subsidiary, *Venus Pharma GmbH*. As stated in the note, the subsidiary's net worth has turned negative by INR 132.10 Lakhs as at the reporting date, which indicates the existence of a material uncertainty that may cast significant doubt on its ability to continue as a going concern.


We have considered management's assessment of the going concern assumption, including their future projections, proposed financial support from the holding company, revival strategies and representations obtained that the subsidiary's financial position is expected to improve and stabilize by the end of the financial year 2025-26.

2. We draw attention to Note 5 of the accompanying Statement, which describes the outstanding share application money amounting to INR 2,859.72 Lakhs in respect of *Venus Pharma GmbH*, a wholly owned subsidiary of the Company. The share allotment against this amount has been pending as it is not mandatory under the applicable laws of Germany.

Management has represented that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations carried out by the Management in FY 2025-26. Although the subsidiary is currently facing financial challenges, the Company has reiterated its intention to provide the necessary financial and operational support during the transition period.

Our conclusion is not modified in respect of these matters.

For J.K Jain & Associates
Chartered Accountants
FRN-004025N



CA Anurag Verma
Partner
M. No. 555033
UDIN: 25555033BMNSRZ8023
Date: 10th November, 2025

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED
30TH SEPTEMBER 2025**

(Rs. In Crores except EPS)

S. No.	PARTICULARS	QUARTER ENDED ON			HALF YEAR ENDED ON		YEAR ENDED ON
		30/09/2025	30/06/2025	30/09/2024	30/09/2025	30/09/2024	31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue						
	(a) Revenue from Operations	192.65	137.13	169.67	329.78	275.53	644.47
	(b) Other Income	1.68	2.72	8.06	4.40	9.62	15.77
	Total Income	194.33	139.85	177.73	334.18	285.15	660.24
2	Expenses						
	(a) Cost of Material Consumed	106.51	71.33	77.41	177.84	147.00	348.82
	(b) Purchase of stock in trade	1.87	2.27	8.38	4.13	17.41	25.04
	(c) Changes in Inventories of finished goods, work-in-progress & Stock in Trade	(1.06)	0.55	23.85	(0.51)	2.55	0.93
	(d) Employee benefits expense	22.03	19.26	19.45	41.29	35.53	72.24
	(e) Depreciation & amortization expense	5.92	5.95	6.17	11.87	11.93	21.62
	(f) Selling, Manufacturing and Administrative expenses	28.43	22.38	24.54	50.81	39.49	104.15
	(g) Research & Development expenses	5.03	3.41	3.14	8.44	6.37	18.29
	Total Expense	168.73	125.16	162.92	293.87	260.26	591.09
3	Profit before taxes (1-2)	25.60	14.70	14.81	40.31	24.89	69.15
4	Exceptional Items	-	-	-	-	-	9.91
5	Profit after exceptional items (3 + 4)	25.60	14.70	14.81	40.31	24.89	79.06
	EBIDTA (3+2e)	31.52	20.65	20.98	52.18	36.82	90.77
6	Tax Expenses						
A	Current Tax	6.45	3.70	3.72	10.15	6.26	18.93
B	Deferred Tax	(0.09)	(0.69)	1.83	(0.79)	4.92	4.65
C	Tax expense related to previous year	-	-	-	-	-	2.93
7	Net Profit / (Loss) for the period (5 - 6)	19.24	11.69	9.26	30.95	13.71	52.55
8	Other Comprehensive Income						
A	(I) Items that will not be reclassified to Profit & loss	(0.12)	(0.12)	(0.04)	(0.24)	(0.09)	(0.48)
B	(I) Items that may be reclassified to Profit & loss	0.63	3.73	2.88	4.36	3.19	0.05
	(II) Income tax relating to items that may be reclassified to Profit & loss	-	-	(0.72)	-	(0.80)	-
C	Total other comprehensive Income Net of Income Tax	0.51	3.61	2.12	4.12	2.29	(0.43)
9	Total comprehensive Income for the period (7+/-8)	19.75	15.30	11.37	35.07	16.00	52.12
10	Paid up equity share capital (Face Value of Equity Shares)	13.37	13.37	13.37	13.37	13.37	13.37
11	Other Equity	10	10	10	10	10	10
12	Earning per share (of Rs. 10/- each)						576.13
	(a) Basic (₹)	14.40	8.75	6.92	23.15	10.25	39.32
	(b) Diluted (₹)	14.40	8.75	6.92	23.15	10.25	39.32



For VENUS REMEDIES LIMITED

 CHAIRMAN & MANAGING DIRECTOR

Unaudited Statement of Standalone Assets and Liabilities		
Particulars	(₹ In Crore)	
	As at 30/09/2025 (Unaudited)	As at 31/03/2025 (Audited)
ASSETS		
Non-Current Assets		
(a) Property, Plant & Equipment	109.88	110.93
(b) Capital Work in Progress	34.01	26.39
(c) Intangible Assets	97.70	103.21
(d) Right of use Assets	13.14	-
(e) Financial Assets		
(i) Investments	0.16	0.16
(ii) Other Financial Assets	35.30	34.30
(f) Other Non-Current Assets	4.20	2.48
Total Non Current Assets	294.39	277.47
Current Assets		
(a) Inventories	106.67	100.49
(b) Financial Assets		
(i) Investment	193.16	84.09
(ii) Trade Receivables	109.54	99.26
(iii) Cash and Cash Equivalents	21.37	55.41
(iv) Others Bank Balances	20.60	22.58
(v) Other Financial Assets	0.31	0.38
(c) Current Tax Assets	9.34	10.86
(d) Other Current Assets	36.25	62.68
Total Current Assets	497.24	435.75
Total Assets	791.63	713.22
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	13.37	13.37
(b) Other Equity	611.20	576.13
Total equity	624.57	589.50
Liabilities		
Non-Current Liabilities		
(a) Provisions	3.19	2.90
(b) Deferred Tax Liabilities (Net)	15.81	15.58
(c) Financial Liabilities		
(i) Lease Liabilities	11.74	-
Total Non-Current Liabilities	30.74	18.48
Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables		
(a) Total outstanding dues of micro enterprises and small enterprises	11.25	6.05
(b) Total outstanding dues of creditors other than micro and small enterprises	83.34	62.56
(ii) Lease Liabilities	1.30	-
(iii) Other Financial Liabilities	35.70	25.35
(b) Other Current Liabilities	2.48	5.20
(c) Provisions	2.25	6.08
Total Current Liabilities	136.32	105.24
Total Equity and Liabilities	791.63	713.22



For VENUS REMEDIES LIMITED



CHAIRMAN & MANAGING DIRECTOR

**UNAUDITED STATEMENT OF STANDALONE CASH FLOW FOR THE PERIOD ENDED 30TH
SEPTEMBER 2025**

(₹ in Crore)

PARTICULARS	For the Year Ended 30/09/2025	For the Year Ended 30/09/2024
	Unaudited	Unaudited
A) CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Tax	40.31	24.89
Adjustment for Depreciation	11.87	11.93
Adjustment for loss/(profit) on sale of Property plant and Equipment	0.07	0.78
Rent Received	(0.21)	(0.20)
Gain on sale of Mutual Funds	(1.55)	(0.75)
Interest Received	(1.22)	(2.07)
Operating Profit before working capital changes	49.27	34.58
Less: Tax Paid	(9.22)	(7.12)
Adjustments for increase /decrease in Current Assets	13.55	(34.06)
Decrease / Increase in Current Liabilities/ Provisions	33.61	30.89
Decrease / Increase in Others Non-Current Assets and Other Financial Assets	(2.73)	(2.93)
Provision for gratuity, leave encashment and Income tax	(4.70)	0.53
Net Cash Flow from operating activities (A)	79.78	21.89
B) CASH FLOW FROM INVESTING ACTIVITIES		
Rent Received	0.21	0.20
Purchase of Property plant and equipment	(12.90)	(2.98)
Right of Use Assets	(13.30)	-
Purchase of Intangible Assets	-	(8.45)
Sale of Property plant and equipment	0.06	0.13
Investment in Mutual Funds / Fixed Deposit	(103.71)	(33.49)
Gain on sale of Mutual Funds	1.55	0.75
Interest Received	1.22	2.07
Net Cash Flow from Investing Activities (B)	(126.87)	(41.77)
C) CASH FLOW FROM FINANCING ACTIVITIES		
Lease Liabilities	13.05	-
Net Cash from Financing Activities (C)	13.05	-
Net Increase in Cash & Cash Equivalents (A+B+C)	(34.04)	(19.88)
Opening Cash & Cash Equivalents	55.41	48.51
Closing Cash & Cash Equivalents	21.37	28.63



For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

Notes to the standalone financial results: -

1. The above Standalone Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 10th November 2025. The statutory auditors of the company have carried out limited review of the above Standalone Financial Result for the quarter and half year ended 30th September 2025, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The Standalone Financial Results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
3. The company has a wholly owned subsidiary named Venus Pharma GmbH in Germany and step-down subsidiary of Venus Pharma GmbH named as Venus Pharma Kft in Hungary.
4. Net worth of the Company's overseas wholly owned subsidiary, *Venus Pharma GmbH*, net worth has been eroded by INR 132.10 Lakhs. But management's assessment for the going concern assumption, including future projections, proposed financial support and revival strategies, the subsidiary's financial position is expected to improve and stabilize by the end of the financial year 2025-26.
5. The share application amounts to INR 2,859.72 Lakhs in respect of Venus Pharma GmbH, a wholly owned subsidiary of the Company is pending for allotment of shares as share allotment against this amount is not a regulatory requirement under the applicable laws of Germany. The Management has reiterated that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations it carried out in FY25.
6. Previous year / period figures have been regrouped/ reclassified wherever necessary.
7. The group has only one reportable segment namely "Pharmaceuticals"



**For and on behalf of Board of Directors
for VENUS REMEDIES LIMITED**


Pawan Chaudhary
(Managing Director)
DIN: 00435503

Date: 10-11-2025